Plain-English translation of NCT04777942 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a combination of two chemotherapy treatments given before surgery—called transartery chemoembolization plus hepatic artery infusion chemotherapy (TACE-HAIC)—can help people with early-stage liver cancer live longer and stay cancer-free longer than surgery alone. Half of the participants will receive this new pre-surgery treatment followed by surgery to remove the tumor, while the other half will have surgery without the pre-treatment chemotherapy.
Early-stage liver cancer can come back even after surgery removes the tumor. Recent studies suggest that giving chemotherapy before surgery might lower the risk of cancer returning, but doctors need to test this in a large trial to know if it really helps patients live longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive the combination chemotherapy treatment through the artery before surgery, followed by an operation to remove the tumor. The other group will proceed directly to surgery. The trial will track how well you recover, whether your cancer comes back, and how long you survive to compare the two approaches.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China